Alle Storys
Keine Story von Lilly ICOS LLC mehr verpassen.


Lilly ICOS' Cialis(R) (tadalafil) Reaches US$1 Billion Global Sales Milestone

Bothell, Washington and Indianapolis (ots/PRNewswire)

- Latest figures confirm success of Cialis in the global ED
Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of
tadalafil(1), a PDE5 inhibitor indicated for the treatment of
erectile dysfunction (ED), announced today that the drug has achieved
US$1 billion in global sales since launching in Europe a little more
than two years ago(2).
In January 2005, tadalafil became the leading ED treatment in
France, a lead it has held through May, based on the latest market
share data(3). It is also performing very well in other countries,
including the United Kingdom, Italy, Germany, United States, Canada,
Australia, Mexico and Brazil(4).
"We are very pleased with the performance of Cialis and the steady
development of the brand since its launch two years ago," said Rich
Pilnik, President of Lilly's EMEA region. "Millions of men suffer
from ED and the growth of the market demonstrates that patients are
speaking to their healthcare providers about ED and seeking treatment
Tadalafil was the second PDE5 inhibitor drug to become available
in Europe. It is currently marketed in approximately 100 countries
including the United States, Australia, Brazil, Mexico, Canada and
across Europe and Asia.
"Passing the US$1 billion mark is an important milestone for Lilly
ICOS and a great accomplishment for the Cialis team," said Paul
Clark, Chairman and Chief Executive Officer of ICOS Corporation.
"Since 2003, men with erectile dysfunction have had a choice of oral
treatments for their condition -- a condition which may impact on
relationships and daily life."
About ED
ED is defined as the consistent inability to attain and maintain
an erection sufficient for sexual intercourse. ED affects an
estimated 189 million men worldwide(5). Experts believe that 80
percent to 90 percent of ED cases are related to a physical or
medical condition, such as diabetes, cardiovascular diseases, and
prostate cancer treatment, while 10 percent to 20 percent are due to
psychological causes(6). In many cases, however, both psychological
and physical factors contribute to the condition(7).
About Lilly ICOS LLC
Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli
Lilly and Company, developed Cialis for the treatment of erectile
dysfunction. ICOS Corporation, a biotechnology company headquartered
in Bothell, Washington, is dedicated to bringing innovative
therapeutics to patients. ICOS is working to develop treatments for
serious unmet medical conditions such as benign prostatic
hyperplasia, pulmonary arterial hypertension, cancer and inflammatory
diseases. Additional information about ICOS is available at
Lilly, a leading innovation-driven corporation is developing a
growing portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers -- through medicines and information -- for some of the
world's most urgent medical needs.
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations,
estimates and projections about the industry, management beliefs and
certain assumptions made by the management of ICOS and Lilly.
Investors are cautioned that matters subject to forward-looking
statements involve risks and uncertainties, including economic,
competitive, governmental, technological, legal and other factors
discussed in the two companies' respective filings with the
Securities and Exchange Commission, which may affect the business and
prospects of the two companies and Lilly ICOS. Results and the timing
and outcome of events may differ materially from those expressed or
implied by the forward-looking statements in this press release. More
specifically, there can be no assurance that Cialis will achieve
commercial success or that competing products will not pre-empt
market opportunities that might exist for the product.
(1) Cialis(R) is a registered trademark of Lilly ICOS LLC. All
other trademarks are the property of their respective owners.
(2) Data on File
(3) IMS Health, IMS MIDAS(TM), May 2005
(4) IMS Health, IMS MIDAS(TM), February 2005
(5) Data were extrapolated from Feldman HA, Goldstein I,
Hatzichistou DG, Krane RJ. Impotence and its Medical and Psychosocial
Correlates: Results of the Massachusetts Male Aging Study, Journal of
Urology. Vol 151, 54-61, January 1994 and World Population Projection
Program of United Nations (2002 Revisions) with indirect
(6) Diseases and Conditions: Impotence, Data accessed July 2005
(7) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342, 24:


Jane Calloway of Lilly, +1-317-651-5870; or Lacy Fitzpatrick of ICOS,

Weitere Storys: Lilly ICOS LLC
Weitere Storys: Lilly ICOS LLC